Brutons Tyrosine Kinase as a New Therapeutic Target

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Brutons Tyrosine Kinase as a New Therapeutic Target

Anti-Cancer Agents in Medicinal Chemistry, 7(6): 624-632.

Author(s): Fatih M. Uckun, Heather E. Tibbles and Alexei O Vassilev.

Affiliation: Parker Hughes Cancer Center,2848 Patton Road, St. Paul, MN 55113, USA.


Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.


Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 7
Issue Number: 6
First Page: 624
Last Page: 632
Page Count: 9
DOI: 10.2174/187152007784111331
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science